AU2004281154A1 - 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of Raf kinase for treatment of cancer - Google Patents

2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of Raf kinase for treatment of cancer Download PDF

Info

Publication number
AU2004281154A1
AU2004281154A1 AU2004281154A AU2004281154A AU2004281154A1 AU 2004281154 A1 AU2004281154 A1 AU 2004281154A1 AU 2004281154 A AU2004281154 A AU 2004281154A AU 2004281154 A AU2004281154 A AU 2004281154A AU 2004281154 A1 AU2004281154 A1 AU 2004281154A1
Authority
AU
Australia
Prior art keywords
compound
substituted
heteroaryl
unsubstituted
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004281154A
Other languages
English (en)
Inventor
Savithri Ramurthy
Paul A. Renhowe
Sharadha Subramanian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Publication of AU2004281154A1 publication Critical patent/AU2004281154A1/en
Assigned to NOVARTIS VACCINES AND DIAGNOSTICS, INC. reassignment NOVARTIS VACCINES AND DIAGNOSTICS, INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: CHIRON CORPORATION
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Structural Engineering (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Reverberation, Karaoke And Other Acoustics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2004281154A 2003-10-16 2004-10-15 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of Raf kinase for treatment of cancer Abandoned AU2004281154A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51185103P 2003-10-16 2003-10-16
US60/511,851 2003-10-16
PCT/US2004/034185 WO2005037285A1 (en) 2003-10-16 2004-10-15 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for treatment of cancer

Publications (1)

Publication Number Publication Date
AU2004281154A1 true AU2004281154A1 (en) 2005-04-28

Family

ID=34465285

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004281154A Abandoned AU2004281154A1 (en) 2003-10-16 2004-10-15 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of Raf kinase for treatment of cancer

Country Status (10)

Country Link
US (3) US7691866B2 (OSRAM)
EP (1) EP1680122A1 (OSRAM)
JP (1) JP2007509059A (OSRAM)
KR (1) KR20070029110A (OSRAM)
CN (1) CN1882345A (OSRAM)
AU (1) AU2004281154A1 (OSRAM)
CA (1) CA2542329A1 (OSRAM)
IL (1) IL174470A0 (OSRAM)
MX (1) MXPA06003607A (OSRAM)
WO (1) WO2005037285A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005206571B2 (en) * 2004-01-23 2010-08-12 Amgen Inc. Compounds and methods of use

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
CA2359244C (en) 1999-01-13 2013-10-08 Bayer Healthcare Llc .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP2324825A1 (en) 2002-02-11 2011-05-25 Bayer Healthcare LLC Aryl ureas with angiogenesis inhibiting activity
US20030216396A1 (en) 2002-02-11 2003-11-20 Bayer Corporation Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
DE602004007382T2 (de) 2003-05-20 2008-04-17 Bayer Pharmaceuticals Corp., West Haven Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
DK1663978T3 (da) 2003-07-23 2008-04-07 Bayer Pharmaceuticals Corp Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US7652009B2 (en) 2004-11-30 2010-01-26 Amgem Inc. Substituted heterocycles and methods of use
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US20060292537A1 (en) * 2005-06-27 2006-12-28 Arcturus Media, Inc. System and method for conducting multimedia karaoke sessions
AU2006322094A1 (en) * 2005-12-08 2007-06-14 Millennium Pharmaceuticals, Inc. Bicyclic compounds with kinase inhibitory activity
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
AU2007275682B2 (en) * 2006-07-20 2012-05-17 Amgen Inc. Substituted pyridone compounds and methods of use
WO2008020203A1 (en) * 2006-08-17 2008-02-21 Astrazeneca Ab Pyridinylquinaz0linamine derivatives and their use as b-raf inhibitors
TW200829566A (en) * 2006-12-08 2008-07-16 Astrazeneca Ab Chemical compounds
US20080198271A1 (en) * 2007-02-20 2008-08-21 Malki Eli Self Operated Computerized Karaoke Recording Booth
CN101808999B (zh) 2007-09-27 2013-02-13 弗·哈夫曼-拉罗切有限公司 用作5ht5a受体拮抗剂的喹啉衍生物
GB0719644D0 (en) 2007-10-05 2007-11-14 Cancer Rec Tech Ltd Therapeutic compounds and their use
US20100261679A1 (en) * 2007-10-18 2010-10-14 James Sutton CSF-1R, Inhibitors, Compositions, and Methods of Use
EP2226315A4 (en) 2007-12-28 2012-01-25 Carna Biosciences Inc 2-aminoquinazoline DERIVATIVE
GB0803018D0 (en) 2008-02-19 2008-03-26 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP2265610B1 (en) * 2008-02-29 2012-12-12 Array Biopharma, Inc. Pyrazole [3, 4-b]pyridine raf inhibitors
CN102015707A (zh) * 2008-02-29 2011-04-13 阵列生物制药公司 Raf抑制剂化合物及其使用方法
WO2009111277A1 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. Imdizo [4. 5-b] pyridine derivatives used as raf inhibitors
EP2265574A1 (en) * 2008-02-29 2010-12-29 Array Biopharma, Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
PL2947072T3 (pl) 2008-03-17 2017-05-31 Ambit Biosciences Corporation 1-(3-(6,7-dimetoksychinazolin-4-yloksy)fenylo)-3-(5-(1,1,1-trifluoro-2-metylopropan-2-ylo)izoksazol-3-ilo)mocznik jako modulator kinazy RAF w leczeniu chorób nowotworowych
EP2381943A1 (en) 2008-12-29 2011-11-02 Fovea Pharmaceuticals Substituted quinazoline compounds
CN102317288A (zh) 2009-02-13 2012-01-11 佛维雅制药公司 作为激酶抑制剂的[1,2,4]三唑并[1,5-a]吡啶
CN102573473B (zh) 2009-06-09 2015-05-27 加利福尼亚资本权益有限责任公司 用作hedgehog 信号转导抑制剂的异喹啉、喹啉和喹唑啉衍生物
FI2440546T3 (fi) * 2009-06-12 2023-03-30 Abivax Ennenaikaisen vanhenemisen ja erityisesti progerian hoitamiseen hyödyllisiä yhdisteitä
US10253020B2 (en) 2009-06-12 2019-04-09 Abivax Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging
KR101630283B1 (ko) * 2009-06-25 2016-06-14 한화테크윈 주식회사 영상 보안 시스템에서 부호화 장치
EA021275B9 (ru) 2009-09-03 2015-08-31 Байоэнердженикс Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение для лечения pask-опосредованного заболевания
US8553906B2 (en) * 2010-02-02 2013-10-08 Creative Technology Ltd Apparatus for enabling karaoke
TW201204723A (en) 2010-06-22 2012-02-01 Fovea Pharmaceuticals Heterocyclic compounds, their preparation and their therapeutic application
HUE037860T2 (hu) 2010-11-19 2018-09-28 Ligand Pharm Inc Heterociklusos aminok és alkalmazásuk
KR101858292B1 (ko) * 2011-01-05 2018-05-15 바이오에너제닉스 Ｐａｓｋ 억제용 헤테로시클릭 화합물
CN107245056A (zh) * 2011-08-26 2017-10-13 润新生物公司 化学实体、组合物及方法
EP2755657B1 (en) 2011-09-14 2017-11-29 Neupharma, Inc. Certain chemical entities, compositions, and methods
US9249110B2 (en) 2011-09-21 2016-02-02 Neupharma, Inc. Substituted quinoxalines as B-raf kinase inhibitors
WO2013049701A1 (en) * 2011-09-30 2013-04-04 Neupharma, Inc. Certain chemical entities, compositions, and methods
JP6073910B2 (ja) 2011-11-09 2017-02-01 キャンサー・リサーチ・テクノロジー・リミテッド ５−（ピリジン−２−イル−アミノ）−ピラジン−２−カルボニトリル化合物及びその治療使用
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
EP2806874B1 (en) 2012-01-25 2017-11-15 Neupharma, Inc. Quinoxaline-oxy-phenyl derivatives as kinase inhibitors
JP6027230B2 (ja) 2012-05-15 2016-11-16 キャンサー・リサーチ・テクノロジー・リミテッド ５−［［４−［［モルホリン−２−イル］メチルアミノ］−５−（トリフルオロメチル）−２−ピリジル］アミノ］ピラジン−２−カルボニトリルおよびその治療上の使用
CN104812389B (zh) 2012-09-24 2020-07-17 润新生物公司 某些化学实体、组合物及方法
US9725421B2 (en) 2012-11-12 2017-08-08 Neupharma, Inc. Substituted quinoxalines as B-raf kinase inhibitors
CN103896922B (zh) * 2012-12-25 2017-05-03 上海科胜药物研发有限公司 新的舒尼替尼盐及其制备方法
EP2757161A1 (en) 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
CN104744446B (zh) * 2013-12-30 2019-06-25 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
EP2974729A1 (en) 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
US10807983B2 (en) 2015-03-16 2020-10-20 Ligand Pharmaceuticals, Inc. Imidazo-fused heterocycles and uses thereof
JP7105774B2 (ja) 2016-12-01 2022-07-25 イグナイタ インコーポレイテッド がん治療のための方法
US11471538B2 (en) 2017-02-10 2022-10-18 INSERM (Institut National de la Santéet de la Recherche Medicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway
EP3732285A1 (en) 2017-12-28 2020-11-04 Tract Pharmaceuticals, Inc. Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
CN113056272A (zh) * 2018-09-21 2021-06-29 光谱医药公司 新的喹唑啉egfr抑制剂
EP3669873A1 (en) 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use ine the traeatment of inflammation diseases
US12528796B2 (en) * 2019-04-15 2026-01-20 Tosk, Inc. Modulators of RAS GTPase
CN111072500B (zh) * 2019-11-15 2022-12-06 山东罗欣药业集团恒欣药业有限公司 一种盐酸氨溴索的制备方法
TW202204348A (zh) 2020-04-07 2022-02-01 美商西爾拉癌症醫學公司 Ｃｈｋ１抑制劑之合成方法
US12180220B2 (en) * 2020-10-14 2024-12-31 Tosk, Inc. Heteroaryl modulators of RAS GTPase
US20220112178A1 (en) * 2020-10-14 2022-04-14 Tosk, Inc. Small Molecule Modulators of RAS GTPase
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2739505A (en) * 1952-02-04 1956-03-27 Gillette Edwin Method and means for producing composite talking pictures
GB900779A (en) * 1959-04-22 1962-07-11 Monsanto Chemicals Quinazolines
US3177218A (en) * 1962-01-17 1965-04-06 Monsanto Chemicals Methylene-bis(2-guanidino-4-methylquinazoline)
US4149190A (en) * 1977-10-17 1979-04-10 Xerox Corporation Automatic gain control for video amplifier
US4408221A (en) * 1981-09-22 1983-10-04 Mccoy Reginald F H Television chroma-key systems
DK190983A (da) * 1982-05-01 1983-11-02 Wellcome Found 2,4-diamino-5-(substituerede)pyrimidiner, fremgangsmaade til deres fremstilling og mellemprodukter derfor
US5051817A (en) * 1988-11-18 1991-09-24 Rohm Co., Ltd. Superimposing system
JP3206619B2 (ja) * 1993-04-23 2001-09-10 ヤマハ株式会社 カラオケ装置
JP3542821B2 (ja) * 1994-03-31 2004-07-14 ヤマハ株式会社 映像合成システムに特徴を有するカラオケ装置
US5541666A (en) * 1994-07-06 1996-07-30 General Instrument Method and apparatus for overlaying digitally generated graphics over an analog video signal
JP3662969B2 (ja) * 1995-03-06 2005-06-22 富士通株式会社 カラオケシステム
US5784118A (en) * 1995-04-21 1998-07-21 Sony Corporation Video signal phase synchronizing method, circuit and synthesizing apparatus
US6400374B2 (en) * 1996-09-18 2002-06-04 Eyematic Interfaces, Inc. Video superposition system and method
JP2957977B2 (ja) * 1997-10-30 1999-10-06 三洋電機株式会社 ビデオカメラ
US6514083B1 (en) * 1998-01-07 2003-02-04 Electric Planet, Inc. Method and apparatus for providing interactive karaoke entertainment
HUP0101275A3 (en) * 1998-03-26 2002-12-28 Japan Tobacco Inc Amide derivatives and pharmaceutical compositions containing them as nociceptin antagonists
US7928239B2 (en) * 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
US20020072047A1 (en) * 1999-12-13 2002-06-13 Michelson Daniel R. System and method for generating composite video images for karaoke applications
CN100335479C (zh) * 1999-12-17 2007-09-05 希龙公司 糖元合成酶激酶3的双环抑制剂
US6978051B2 (en) * 2000-03-06 2005-12-20 Sony Corporation System and method for capturing adjacent images by utilizing a panorama mode
KR20020026374A (ko) * 2000-06-20 2002-04-09 요트.게.아. 롤페즈 가라오케 시스템
AU2001295791A1 (en) * 2000-11-02 2002-05-15 Astrazeneca Ab 4-substituted quinolines as antitumor agents
ATE355272T1 (de) 2001-04-20 2006-03-15 Bayer Pharmaceuticals Corp Inhibierung der raf-kinase durch chinolin-, isochinolin- oder pyridin-harnstoffe
US7035915B1 (en) * 2001-09-05 2006-04-25 Cisco Technology, Inc. Method and apparatus for IP address assignment
WO2003024448A2 (en) * 2001-09-14 2003-03-27 Methylgene, Inc. Inhibitors of histone deacetylase
MXPA05011103A (es) * 2003-04-16 2005-12-12 Hoffmann La Roche Compuestos de quinazolina.
US20070047834A1 (en) * 2005-08-31 2007-03-01 International Business Machines Corporation Method and apparatus for visual background subtraction with one or more preprocessing modules
US7570881B2 (en) * 2006-02-21 2009-08-04 Nokia Corporation Color balanced camera with a flash light unit

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005206571B2 (en) * 2004-01-23 2010-08-12 Amgen Inc. Compounds and methods of use
AU2005206571B8 (en) * 2004-01-23 2010-09-02 Amgen Inc. Compounds and methods of use

Also Published As

Publication number Publication date
US20050084835A1 (en) 2005-04-21
EP1680122A1 (en) 2006-07-19
WO2005037285A1 (en) 2005-04-28
CN1882345A (zh) 2006-12-20
US20050085482A1 (en) 2005-04-21
MXPA06003607A (es) 2006-06-05
US20090317359A1 (en) 2009-12-24
CA2542329A1 (en) 2005-04-28
KR20070029110A (ko) 2007-03-13
US7691866B2 (en) 2010-04-06
JP2007509059A (ja) 2007-04-12
IL174470A0 (en) 2006-08-01

Similar Documents

Publication Publication Date Title
US7691866B2 (en) 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of Raf kinase
US7423150B2 (en) Substituted benzazoles and methods of their use as inhibitors of Raf kinase
CN100515419C (zh) 取代的吲哚及其作为Raf激酶抑制剂的应用
US8299108B2 (en) Substituted benzazoles and methods of their use as inhibitors of raf kinase
HK1067945B (en) Substituted benzazoles and use thereof as raf kinase inhibitors
HK1078779B (en) Substituted benzazoles and use thereof as raf kinase inhibitors

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application